IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v467y2010i7313d10.1038_nature09328.html
   My bibliography  Save this article

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

Author

Listed:
  • Marina Cavazzana-Calvo

    (Clinical Investigation Center in Biotherapy, Groupe Hospitalier Universitaire Ouest, Inserm/Assistance Publique–Hôpitaux de Paris, Paris 75015, France
    University Paris-Descartes)

  • Emmanuel Payen

    (CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
    Inserm U962 and University Paris XI, CEA-iMETI, Fontenay-aux-Roses 92265, France
    Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Olivier Negre

    (CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
    Inserm U962 and University Paris XI, CEA-iMETI, Fontenay-aux-Roses 92265, France
    Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France
    Genetix-France, CEA-iMETI, Fontenay-aux-Roses 92265, France)

  • Gary Wang

    (University of Pennsylvania School of Medicine)

  • Kathleen Hehir

    (Genetix Pharmaceuticals)

  • Floriane Fusil

    (CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
    Inserm U962 and University Paris XI, CEA-iMETI, Fontenay-aux-Roses 92265, France
    Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Julian Down

    (Genetix Pharmaceuticals)

  • Maria Denaro

    (Genetix Pharmaceuticals)

  • Troy Brady

    (University of Pennsylvania School of Medicine)

  • Karen Westerman

    (Genetix Pharmaceuticals
    Brigham & Women’s Hospital and Harvard Medical School)

  • Resy Cavallesco

    (Brigham & Women’s Hospital and Harvard Medical School)

  • Beatrix Gillet-Legrand

    (Genetix-France, CEA-iMETI, Fontenay-aux-Roses 92265, France)

  • Laure Caccavelli

    (Clinical Investigation Center in Biotherapy, Groupe Hospitalier Universitaire Ouest, Inserm/Assistance Publique–Hôpitaux de Paris, Paris 75015, France
    University Paris-Descartes)

  • Riccardo Sgarra

    (University of Trieste)

  • Leila Maouche-Chrétien

    (CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
    Inserm U962 and University Paris XI, CEA-iMETI, Fontenay-aux-Roses 92265, France)

  • Françoise Bernaudin

    (Centre Hospitalier Intercommunal de Créteil)

  • Robert Girot

    (Hôpital Tenon, Paris 75020, France)

  • Ronald Dorazio

    (Genetix Pharmaceuticals)

  • Geert-Jan Mulder

    (Genetix Pharmaceuticals)

  • Axel Polack

    (Genetix Pharmaceuticals)

  • Arthur Bank

    (Columbia University College of Physicians and Surgeons)

  • Jean Soulier

    (Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Jérôme Larghero

    (Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Nabil Kabbara

    (Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Bruno Dalle

    (Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Bernard Gourmel

    (Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Gérard Socie

    (Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Stany Chrétien

    (CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
    Inserm U962 and University Paris XI, CEA-iMETI, Fontenay-aux-Roses 92265, France
    Brigham & Women’s Hospital and Harvard Medical School)

  • Nathalie Cartier

    (Inserm UMR745, University Paris-Descartes)

  • Patrick Aubourg

    (Inserm UMR745, University Paris-Descartes)

  • Alain Fischer

    (Clinical Investigation Center in Biotherapy, Groupe Hospitalier Universitaire Ouest, Inserm/Assistance Publique–Hôpitaux de Paris, Paris 75015, France
    University Paris-Descartes)

  • Kenneth Cornetta

    (Indiana University)

  • Frédéric Galacteros

    (Hopital Henri Mondor, AP-HP, Créteil 94000, France)

  • Yves Beuzard

    (CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI)
    Inserm U962 and University Paris XI, CEA-iMETI, Fontenay-aux-Roses 92265, France
    Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Eliane Gluckman

    (Bone Marrow Transplantation and Biochemistry, University Paris VII, Institute of Hematology, Hôpital Saint-Louis, AP-HP, Paris 75010, France)

  • Frederick Bushman

    (University of Pennsylvania School of Medicine)

  • Salima Hacein-Bey-Abina

    (Clinical Investigation Center in Biotherapy, Groupe Hospitalier Universitaire Ouest, Inserm/Assistance Publique–Hôpitaux de Paris, Paris 75015, France
    University Paris-Descartes)

  • Philippe Leboulch

Abstract

Gene therapy success Blood disorders caused by abnormal β-globin — β-thalassaemia and sickle cell disease — are the most prevalent inherited disorders worldwide, with patients often remaining dependent on blood transfusions throughout their lives. So a report of the successful use of gene therapy in a case of severe β-thalassaemia — using a lentiviral vector expressing the β-globin gene — is an eagerly awaited event. More than two years after gene transfer, the adult male patient has been transfusion-independent for 21 months. The therapeutic benefit seems to result from a dominant, myeloid-biased cell clone that may remain benign, although it could yet develop into leukaemia — a reminder that gene therapy is still at an early stage.

Suggested Citation

  • Marina Cavazzana-Calvo & Emmanuel Payen & Olivier Negre & Gary Wang & Kathleen Hehir & Floriane Fusil & Julian Down & Maria Denaro & Troy Brady & Karen Westerman & Resy Cavallesco & Beatrix Gillet-Leg, 2010. "Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia," Nature, Nature, vol. 467(7313), pages 318-322, September.
    • Handle: RePEc:nat:nature:v:467:y:2010:i:7313:d:10.1038_nature09328
    DOI: 10.1038/nature09328
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature09328
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature09328?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Suk See Ravin & Siyuan Liu & Colin L. Sweeney & Julie Brault & Narda Whiting-Theobald & Michelle Ma & Taylor Liu & Uimook Choi & Janet Lee & Sandra Anaya O’Brien & Priscilla Quackenbush & Tyra Estwick, 2022. "Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    2. Sebastian Wagner & Christoph Baldow & Andrea Calabria & Laura Rudilosso & Pierangela Gallina & Eugenio Montini & Daniela Cesana & Ingmar Glauche, 2022. "Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    3. Francesca Tucci & Stefania Galimberti & Luigi Naldini & Maria Grazia Valsecchi & Alessandro Aiuti, 2022. "A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders," Nature Communications, Nature, vol. 13(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:467:y:2010:i:7313:d:10.1038_nature09328. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.